1. Prospective studies are recommended to follow up persons with prehypertension to determine more accurately if tubular dysfunction precedes glomerular dysfunction and to determine other factors which may contribute to the development of renal dysfunction in essential hypertension.
2. Blood pressure especially systolic blood pressure should be treated to target to prevent or delay the development of renal complications.
3. Patients with hypertension should have their glomerular and tubular functions assessed regularly.
77
4. Regular screening programmes with blood pressure and anthropometric measurements should be conducted for early detection of hypertension and other cardiovascular diseases with subsequent education of the masses.
78 REFERENCES
1. National Kidney Foundation. Clinical practical guidelines for chronic kidney disease:
evaluation, classification and stratification. AMJ kidney. 2002; 39(2):51 - 266.
2 Richard JJ, Dan IF, Takakiko N, et al. Pathogenesis of essential hypertension in historical paradigms and modern insights. J Hypertens. 2008; 26: 381 - 391.
3 Edouard B, Gregory YH, George LB, (eds) Hypertension Principles and practice. First edition. Taylor and Francis ( publishers), New York: 2005; 101 - 167.
4 Addo J, Smeeth L, Leon DA. Hypertension in sub-Saharan Africa: a systematic review.
Hypertens. 2007; 50: 1012-1018.
5 Ojogwu LI, Ofili UG. Morbidity and mortality from postpartum hypertension in Nigerian women. Afr J Med med Sci. 1993; 22: 11-16.
6 Pavithran P, Madanmohan T, Nandeesha H. Sex differences in short-term heart rate variability in patients with newly diagnosed essential hypertension. J Clin Hypertens;
2008; 10: 904-910.
7 Kadiri S, Walker O, Salako BL, Akinkugbe O. Blood pressure and correlates in urbanised workers in Ibadan, Nigeria - a revisit. J Hum hypertens. 1999; 13: 23 - 27.
8 Alebiosu CO, Ayodele OE. The global burden of chronic kidney disease and the way forward. Ethn Dis. 2005; 15: 520 - 521.
9 Akinsola W, Odesanmi WO, Ogunniyi JO, Ladipo GO. Diseases causing chronic renal failure in Nigerians--a prospective study of 100 cases. Afr J Med med Sci. 1989; 18: 131-137.
79
10 Ayodele OE, Alebiosu CO, Akinwusi PO, et al. Target organ damage and associated clinical conditions in newly diagnosed hypertensives attending a tertiary health facility.
Niger J Clin Pract. 2007; 10: 319-325.
11 Adedoyin RA, Mbada CE, Balogun MO, et al. Prevalence and pattern of hypertension in a semiurban community in Nigeria. Eur J Cardiovasc Prev Rehabil. 2008; 15: 683-687.
12 Bonfanti F, Corrocher R, Bertinato L, et al. Incidence of retinal and renal complications in arterial hypertension. Minerva Cardioangiol. 1986; 34: 99-105.
13 Perny HM, Miller JP, Fornoff JR, et al. Early predictors of 15 year end stage renal disease in hypertensive patients. Hypertension. 1995; 25: 587 - 94.
14 Kadiri S, Arije A. Temporal variations and meteorological factors in hospital admissions of chronic renal failure in south west Nigeria. West Afr J Med. 1999; 18: 49-51.
15 Ojogwu LI. The pathological basis of endstage renal disease in Nigerians: experience from Benin City. West Afr J Med. 1990; 9: 193-196.
16 Steddon S, Ashman N, Chesser A, Cunningham J(eds). Oxford handbook of nephrology and hypertension. First edition. Oxford university press(publishers), New York: 2007;95 - 101.
17 Saraladevi N. End stage renal disease in sub saharan and South Africa. Kidney Int. 2003;
83: 118 - 122.
18 Arije A, Thomas J, Kadiri S. Rapidly progressive glomerulonephritis in adult Nigerians:
a report of 4 cases. Afr J Med Med Sci. 2002; 31: 75-77.
19 Pabico RC, Cala AR, McKenna BA, Freeman RB. Massive proteinuria and its effects on renal tubular functions. Proc Eur Dial Transplant Assoc. 1977; 14: 495-500.
80
20 Akinkugbe OO. Tropical nephropathy--an overview. Afr J Med Med Sci. 1992; 21: 3-7.
21 Per A, Peterson BA, Ingemar B. Differentiation of glomerular, tubular and normal proteinuria: determinations of urinary excretion of B2 microglobulin, albumin and total protein. J Clin Invest. 1969; 48: 1189 - 1198.
22 Skalova S. The diagnostic role of urinary NAG in the detection of renal tubular impairment. Acta Medica. 2005; 48: 75 - 80.
23 Kadiri S, Ajayi SO. Variability in the relationship between serum creatinine and
creatinine clearance in hypertensives and normotensives with normal renal function. Afr J Med med Sci. 2000; 29: 93-96.
24 Sanusi AA, Akinsola A, Ajayi AA. Creatinine clearance from serum creatinine values:
evaluation and comparison of five prediction formulae in Nigerian patients. Afri J Med med Sci. 2000; 29: 7 - 11.
25 Wibell L. Aspects on tubular proteinuria. Ups J Med Sci. 1985; 90: 5 - 14.
26 Addo J, Amoah AG, Koram KA. The changing patterns of hypertension in Ghana: a study of four rural communities in the Ga District. Ethn Dis. 2006; 16: 894-899.
27 Familoni BO, Ogun SO, Aina AO. Knowledge and awareness of hypertension among patients with systemic hypertension. Cardiovasc J S Afr. 2005; 16: 89 - 93.
28 Blanchard A, Poussou R, Houillier P. Exploration of renal tubular functions. Nephrol Ther. 2009; 5: 68-83.
29 Saito T, Miyahara T. Neural control of renal circulation and renal tubular functions.
Nippon Jinzo Gakkai Shi. 1983; 25: 876-877.
81
30 Ojogwu LI, Anah CO. Renal failure and hypertension in tropical Africa--a pre-dialysis experience from Nigeria. East Afr Med J. 1983; 60: 478-484.
31 Sharma AM. Renal tubular dysfunction and acidosis. Nephrol Dial Transplant. 1995; 10:
1544-1545.
32 Akinkugbe OO. The Nigerian hypertension programme. J Hum Hypertens. 1996; 10 Suppl 1: S43-6.
33 Remuzzi G. Abnormal protein traffic through the glomerular barrier induces proximal tubular cell dysfunction and causes renal injury. Curr Opin Nephrol Hypertens. 1995; 4:
339-342.
34 Addo J, Smeeth L, Leon DA. Prevalence, detection, management, and control of hypertension in Ghanaian civil servants. Ethn Dis. 2008; 18: 505-511.
35 Kadiri S, Olutade BO. The clinical presentation of malignant hypertension in Nigerians. J Hum Hypertens. 1991; 5: 339 - 343.
36 Viberti GC. Introduction to a structural basis for renal and vascular complications in diabetes and hypertension. J Hypertens Suppl. 1992; 10: S1-4.
37 Lee RV, Enhorning G. Essential hypertension in men and women. Ann Intern Med. 1988;
108: 148 - 151.
38 de la Sierra A, Lluch MM, Coca A, A et al. Assessment of salt sensitivity in essential hypertension by 24-h ambulatory blood pressure monitoring. Am J Hypertens. 1995; 8:
970-977.
39 Tuck ML. Obesity, the sympathetic nervous system, and essential hypertension.
Hypertension. 1992; 19: I67-177.
82
40 Tarazi RC. Pathophysiology of essential hypertension. Role of the autonomic nervous system. Am J Med. 1983; 75: 2-8.
41 Jeunemaitre X. Renin-angiotensin-aldosterone system polymorphisms and essential hypertension: where are we? J Hypertens. 2003; 21: 2219-2222.
42 Mahmud A, Feely J. Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension. Am J Hypertens. 2005; 18: 50-55.
43 Ando K, Fujita T. Abnormal renal hemodynamics in salt-sensitive patients with essential hypertension. Jpn Circ J. 1985; 49: 984-989.
44 Gur M, Yilmaz R, Demirbag R, et al. Relationship between impaired elastic properties of aorta with left ventricle geometric patterns and left ventricle diastolic functions in
patients with newly diagnosed essential hypertension. Int J Clin Pract. 2006; 60: 1357-1363.
45 Karaye KM, Okeahialam BN, Wali SS. Cardiovascular risk factors in Nigerians with systemic hypertension. Niger J Med. 2007; 16: 119-124.
46 Moritz A, Oldt M. Arteriolar sclerosis in hypertensive and nonhypertensive individuals.
Am J Pathol. 1937; 13: 679 - 728.
47 Hannila-Handelberg T, Kontula K, Tikkanen I, et al. Common variants of the beta and gamma subunits of the epithelial sodium channel and their relation to plasma renin and aldosterone levels in essential hypertension. BMC Med Genet. 2005; 6: 4 - 9.
48 Lantelme P, Rohrwasser A, Vincent M, et al. Significance of urinary angiotensinogen in essential hypertension as a function of plasma renin and aldosterone status. J Hypertens.
2005; 23: 785-792.
83
49 Zoccali C, Usherwood T, Brown JJ, et al. Hypertension. A comparison of the effects of angiotensin II infusion and variations in salt intake on plasma aldosterone levels in normal subjects, patients with essential hypertension and patients with
hyperaldosteronism. J Steroid Biochem. 1983; 19: 327-331.
50 Vaudo G, Schillaci G, Evangelista F, et al Arterial wall thickening at different sites and its association with left ventricular hypertrophy in newly diagnosed essential
hypertension. Am J Hypertens. 2000; 13: 324-331.
51 Vlasses PH. Hypertension: development, classification, and treatment. Etiology,
pathophysiology, and diagnosis. Am J Pharm Sci Support Public Health. 1975; 147: 78-86.
52 Fabris B, Bortoletto M, Candido R, et al. Genetic polymorphisms of the renin-angiotensin-aldosterone system and renal insufficiency in essential hypertension. J Hypertens. 2005; 23: 309-316.
53 Elijovich F, Laffer CL. Participation of renal and circulating endothelin in salt-sensitive essential hypertension. J Hum Hypertens. 2002; 16: 459-467.
54 Ferri C, Bellini C, Desideri G, et al. Salt-sensitivity is associated with a
hyperinsulinaemic and hyperglycaemic response to atrial natriuretic peptide infusion in human essential hypertension. Diabetologia. 1994; 37: 308-312.
55 Resnick LM, Nicholson JP, Laragh JH. Alterations in calcium metabolism mediate dietary salt sensitivity in essential hypertension. Trans Assoc Am Physicians. 1985; 98:
313-321.
56 Alebiosu CO. An update on 'progression promoters' in renal diseases. J Natl Med Assoc.
2003; 95: 30-42.
84
57 Aviv A. Cellular calcium and sodium regulation, salt-sensitivity and essential hypertension in African Americans. Ethn Health. 1996; 1: 275-281.
58 Kincaid-Smith P. Hypothesis: obesity and the insulin resistance syndrome play a major role in end-stage renal failure attributed to hypertension and labelled 'hypertensive nephrosclerosis'. J Hypertens. 2004; 22: 1051-1055.
59 Friedman GD, Selby JV, Quesenberry CP, et al. Precursors of essential hypertension:
body weight, alcohol and salt use, and parental history of hypertension. Prev Med. 1988;
17: 387-402.
60 Trimarco B, De Simone A, Cuocolo A, et al. Role of prostaglandins in the renal handling of a salt load in essential hypertension. Am J Cardiol. 1985; 55: 116-121.
61 Obel AO, Kofi T, Ellison RH, Mugambi M. Dietary sodium/potassium ratio in salt substitute and its putative significance in essential hypertension. East Afr Med J. 1985;
62: 507-514.
62 Soubrier F. Search for the genes of human essential hypertension. J Hypertens Suppl.
1993; 11: S20-6.
63 Say YH, Ling KH, Duraisamy G, et al. Angiotensinogen M235T gene variants and its association with essential hypertension and plasma renin activity in Malaysian subjects: a case control study. BMC Cardiovasc Disord. 2005; 5: 7 - 11.
64 Addo J, Smeeth L, Leon DA. Hypertensive target organ damage in Ghanaian civil servants with hypertension. PLoS One. 2009; 4: 6672 - 6678.
65 Ayodele OE, Alebiosu CO, Salako BL. Differential control of systolic and diastolic blood pressure in blacks with essential hypertension. J Natl Med Assoc. 2004; 96: 310-314.
85
66 Ukoli VA. Admission of patients at the University of Benin Teaching Hospital, Nigeria.
East Afr Med J. 2007; 74: 329 - 335.
67 Kimmelstein P, Wilson CB. Benign and malignant hypertension and nephrosclerosis. Am J Pathol. 1936; 12: 45 - 81.
68 Ojogwu LI, Ukoli FA. A follow up study of adult nephrotic syndrome in Nigerians:
outcome and predictors of endstage renal failure. Afr J Med Med Sci. 1993; 22: 43-50.
69 Perneger TV, Whelton PK, Klag MJ, Rossiter KA. Diagnosis of hypertensive end stage renal disease:effect of patient's race. AM J Epidemiol. 1995; 141: 10 - 15.
70 Bakris GL, Weir MR, Shanifar S, et al. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med. 2003; 163:
1555 - 1565.
71 Karet FE, Lifton RP. Mutations contributing to human blood pressure variation. Recent Prog Horm Res. 1997; 52: 263 - 276.
72 Brenner BM, Cooper ME, De zeeuw D, et al. Effects of losartan on renal and
cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med.
2001; 345: 861 - 869.
73 Garcia Nieto V, Luis Yanes MI, Callejon A. Proximal renal tubular dysfunction in insulin-dependent diabetes mellitus. Nefrologia. 2001; 21 Suppl 3: 32-38.
74 Schultz CJ, Dalton RN, Neil HA, et al. Markers of renal tubular dysfunction measured annually do not predict risk of microalbuminuria in the first few years after diagnosis of Type I diabetes. Diabetologia. 2001; 44: 224-229.
86
75 Perry HM, Miller JP, Baty JD, et al. Pretreatment blood pressure as a predictor of 21 - year mortality. AM J Hypertens. 2000; 13: 724 - 733.
76 Ayodele OE, Egbewale BE, Alebiosu CO. Kidney function and clinical correlates in newly diagnosed hypertensives attending a university teaching hospital in southwest Nigeria. Afr J Med med Sci. 2007; 36: 95-101.
77 Bihorac A, Tezcan H, Ozener C, et al. Association between salt sensitivity and target organ damage in essential hypertension. Am J Hypertens. 2000; 13: 864-872.
78 Claudio B, Concetta P, Virginia R. Amodern approach to selectivity of proteinuria and tubulointerstitial damage in nephrotic syndrome. Kidney Int. 2000; 58: 1523 - 1755.
79 Kullo IJ, Malik AR, Santos S, et al. Association of cardiovascular risk factors with microvascular and conduit artery function in hypertensive subjects. Am J Hypertens.
2007; 20: 735-742.
80 Odili AN. Prevalence and clinical correlates of microalbuminuria in newly diagnosed hypertensive subjects. Niger J Med. 2008; 17: 452-456.
81 Holm J, Hemmingsen L, Nielsen NV. Low-molecular-mass proteinuria as a marker of proximal renal tubular dysfunction in normo- and microalbuminuric non-insulin-dependent diabetic subjects. Clin Chem. 1993; 39: 517-519.
82 Al-Bander HA, Weiss RA, Humphreys MH, Morris RC, Jr. Dysfunction of the proximal tubule underlies maleic acid-induced type II renal tubular acidosis. Am J Physiol. 1982;
243: 604-611.
83 Grillenberger A, Weninger M, Lubec G. Determination of urinary low molecular weight proteins for the diagnosis of tubular damage. Pediatr Nephrol. 1987; 22: 229 - 234.
87
84 Aperia A, Broberger U. Beta-2-microglobulin, an indicator of renal tubular maturation and dysfunction in the newborn. Acta Paediatr Scand. 1979; 68: 669-676.
85 Hatano M. Clinical study of tubular creatinine secretion in renal dysfunction. Nippon Jinzo Gakkai Shi. 1991; 33: 1097-1104.
86 Golubovic E, Stefanovic V, Zivic S. Diagnosis of renal tubular dysfunction in insulin-dependent diabetes mellitus. Srp Arh Celok Lek. 1996; 124 1: 43-44.
87 Piscator M. Early detection of tubular dysfunction. Kidney Int. 1991; 34: 15 - 17.
88 Kamar N, Allard J, Ribes D, et al. Assessment of glomerular and tubular functions in renal transplant patients receiving cyclosporine A in combination with either sirolimus or everolimus. Clin Nephrol. 2005; 63: 80-86.
89 Hei ZQ, Li XY, Shen N, et al. Prognostic values of serum cystatin C and beta2 microglobulin, urinary beta2 microglobulin and N-acetyl-beta-D-glucosaminidase in early acute renal failure after liver transplantation. Chin Med J (Engl). 2008; 121: 1251-1256.
90 Drueke T, Foley RN, . Introduction: Improving outcomes in chronic kidney disease.
Kidney Int. 2006; 70: 51 - 54.
91 Lifton RP, Dluhy RG, Powers M, et al. A chimaeric 11 beta - hydroxylase aldosterone synthase gene causes glucocorticoid remedial aldosteronism and human hypertension.
Nature. 1992; 355: 262 - 265.
92 Sonkar GK, Usha A, Singh RG. A preliminary study on the significant value of beta-2-microglobulin over serum creatinine in renal transplant rejection and renal failure.
Singapore Med J. 2008; 49: 786 - 790.
88
93 Kowal NE, Zirkes M. Urinary cadmium and beta 2-microglobulin: normal values and concentration adjustment. J Toxicol Environ Health. 1983; 11: 607-624.
94 Ikeda M, Ezaki T, Tsukahara T, et al. Critical evaluation of alpha1- and
beta2-microglobulins in urine as markers of cadmium-induced tubular dysfunction. Biometals.
2004; 17: 539-541.
95 A'Court C. 10-minute consultation. Newly diagnosed hypertension. BMJ. 2002; 324:
1375 - 1379.
96 Kaplan NM. Microalbuminuria: a risk factor for vascular and renal complications of hypertension. Am J Med. 1992; 92: 8S-12S.
97 Zeller A, Sigle JP, Battegay E, Martina B. Value of a standard urinary dipstick test for detecting microalbuminuria in patients with newly diagnosed hypertension. Swiss Med Wkly. 2005; 135: 57-61.
98 Oviasu VO, Okupa FE. Arterial blood pressure and hypertension in Benin in the equatorial forest zone of Nigeria. Trop Geogr Med. 1980; 32: 241-244.
99 Ayodele OE, Alebiosu CO, Salako BL et al. Target organ damage and associated clinical conditions among Nigerians with treated hypertension. Cardiovasc JS Afr 2005; 16: 89 - 93
100 Anah CO. Hypertension in Nigeria, some special problems and features. East Afr Med J 1980; 57:416 - 420
89 APPENDIX 1 SECTION A
1. Serial No 2. Hosp No:
3 Phone no:
Demographic Data 3. Initials:
4. Address:
5. Age(last birthday):
6. Gender: 1. male 2. female
7. Marital status: 1. Single 2. Married 3. Divorced/separated 4. Widowed 8. Tribe :
9. Religion: 1. Christian 2. Islam 3. Others 10. Occupation (specify):_____________________________
11. Highest educational level:
SECTION B: History of hypertension 12. Date of diagnosis
13 Family history of hypertension 0 yes 1 no 14. Family history of DM 0 yes 1 no 15. Past medical history
90
16. Alcohol intake 1 yes 2 no
17. Tobacco use 1 yes 2 no
SECTION C: Clinical evaluation
18. Systolic Blood Pressure
19. Diastolic Blood Pressure 20. Weight
21. Height 22. BMI
23. Waist Circumference 24. Hip Circumference
SECTION D: Laboratory investigation 25. Serum Cr
26. eGFR 27. Urine Ph
28. Urine Specific Gravity
29. Proteinuria/ Microalbuminuria
91 30. Urine Microscopy
31. Urinary β2 Microglobulin 32. Serum electrolytes, urea 33. Urinalysis
92